News
Efficacy of Luspatercept in 1st Line Treatment of Anemia Due to Low-Risk Myelodysplastic Syndrome
A planned interim analysis of the COMMANDS study showed a greater benefit of the innovative treatment with luspatercept compared to the established treatment with epoetin alfa in patients with anemia due to low-risk myelodysplastic syndrome (MDS) and untreated with erythropoiesis-stimulating agents (ESA). The results were published in June 2023 in the journal Lancet.
HPD 2024: Czech data from real-world practice confirm that mucolytic treatment can reduce COPD exacerbations, even in the future
Chronic obstructive pulmonary disease (COPD) is a global issue. Does it create the same burden…
HPD 2024: Bronchitis as an Early Feature of PreCOPD, Role of Mucus Plugs in COPD, and New Findings on Their Exacerbations
Exacerbations of chronic obstructive pulmonary disease (COPD) significantly affect disease…
Benefit of Oral Semaglutide for Patients with Type 2 Diabetes in the General Practitioner's Office
Oral semaglutide is a modern antidiabetic suitable within primary care for people with type 2 diabetes,...
Targeting HER2 is Clinically Meaningful Even with Its Low Expression
Distinguishing HER2 receptor expression status on the surface of breast cancer tumor cells as…
A device the size of a matchbox will help treat obstructive sleep apnea
Obstructive sleep apnea, also known as sleep apnea syndrome, is the second most common sleep…
Current Recommendations of the International League Against Epilepsy for the Treatment of Seizures in Newborns
In 2023, a team of experts in neurology, neonatology, and pediatrics, along with representatives of…
Epilepsy with Generalized Tonic-Clonic Seizures in an Adolescent Patient – A Case Study
This is the story of Anička, a 16-year-old girl who has been treated for epilepsy since she was 14.…
INFOGRAPHIC: Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy
Obstructive hypertrophic cardiomyopathy (HCM) is most commonly caused by disorders of cardiac muscle...
CASE STUDY: Key Benefits of GLP-1RA in Diabetes Therapy in the Office of a General Practitioner
Modern therapy using glucagon-like peptide-1 receptor agonists (GLP-1RA) offers diabetics highly effective...